Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Symptoms and Survivorship

Type: Poster Session

Time: Monday June 3, 1:15 PM to 4:15 PM

Location: Hall A

Association of obesity with breast cancer outcome in relation to cancer subtypes.

Sub-category:
Health Promotion

Category:
Symptoms and Survivorship

Meeting:
2019 ASCO Annual Meeting

Abstract No:
11557

Poster Board Number:
Poster Session (Board #249)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 11557)

Author(s): Ana Elisa Lohmann, Sara V. Soldera, Isabel Pimentel, Domen Ribnikar, Marguerite Ennis, Eitan Amir, Pamela Jean Goodwin; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Princess Margaret Cancer Centre, Toronto, ON, Canada; Mount Sinai Hospital- University of Toronto, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada

Abstract Disclosures

Abstract:

Background: Obesity at breast cancer (BC) diagnosis is associated with poor outcome, although the magnitude of effect in different BC subtypes is uncertain. Here we report on the association of obesity at BC diagnosis with disease-free (DFS) and overall survival (OS) in the following subtypes: (i) hormone receptor (ER/PgR) +ve, HER2-ve, (ii) HER2+ve, any ER/PgR and (iii) triple negative (TN). Methods: We searched MEDLINE, EMBASE and COCHRANE databases to December 31, 2018 and meeting presentations (past 5 years) using predefined search terms. Study eligibility, data abstraction were performed independently by two authors; those reporting hazard ratios (HR) for obesity and DFS/OS in BC subtypes were included. Using Review Manager pooled HRs were computed and weighted using generic inverse variance in fixed and random effects models (results were similar, random effects are presented). Results: Of 10,702 titles, 26 studies (108,793 patients) were included. Pooled HR for DFS for obese vs non-obese were (i) ER/PgR+ve HER2-ve 1.21 (95% Confidence interval, CI; 1.12-1.31, p < 0.00001), (ii) HER2+ve, any ER/PgR 1.16 (95%CI, 1.06-1.26; p = 0.0006) and (iii) TN, 1.13 (95%CI; 1.05-1.22 p = 0.002). Pooled HRs for OS were (i) ER/PgR+ve, HER2-ve 1.45 (95%CI; 1.30-1.62 p < 0.00001), (ii) HER2+ve any ER/PgR 1.21 (95%CI; 1.10-1.34 p = 0.0001) and (iii) TN 1.13 (95%CI, 1.04-1.23, p = 0.003).PooledHR for OS (but not DFS) were somewhat higher in observational vs interventional studies in (i) ER/PgR+ve, HER2-ve 1.57 vs 1.36, HER2+ve any ER/PgR (ii) 1.37 vs 1.09 but not (iii) TN 1.12 vs 1.22 (p = 0.21, 0.03 and 0.48, respectively). Conclusions: Obesity was associated with a worse outcome in all BC subtypes. Higher HR for OS in observational studies in (i) ER/PgR+ve, HER2- and (ii) HER2+ve any ER/PgR BC may reflect selection of healthier patients for intervention trials.

 
Other Abstracts in this Sub-Category:

 

1. Effects of a structured intervention program to improve physical activity (PA) of adolescents and young adult cancer survivors (AYAs): Final results of the randomized Motivate AYA–MAYA trial.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11518 First Author: Jannike Lisa Salchow
Category: Symptoms and Survivorship - Health Promotion

 

2. Physiological and psychosocial effects of a highly structured exercise program on breast cancer survivorship.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11558 First Author: Judy A. Tjoe
Category: Symptoms and Survivorship - Health Promotion

 

3. Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.

Meeting: 2019 ASCO Annual Meeting Abstract No: 11559 First Author: Lawson Eng
Category: Symptoms and Survivorship - Health Promotion

 

More...